Business Wire

Booking.com and Antom Partner to Expand Local Payment Options Across Asia

15.1.2025 04:47:00 CET | Business Wire | Press release

Share

Strategic partnership to streamline payment solutions and elevate traveller experience, introducing over 40 new payment methods across 8 key Asian markets

Booking.com, one of the world’s leading travel companies, and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership which will enhance the payment experience for Booking.com customers by integrating diverse payment options across key markets in Asia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114445080/en/

This partnership will enable Booking.com to deliver a more tailored customer experience while unlocking business opportunities across China’s Hong Kong SAR, Indonesia, Japan, Malaysia, Singapore, South Korea, Thailand, and the Philippines — markets with a combined population of approximately 680 million. Each market presents distinct challenges, including varying payment methods, currencies and regulatory frameworks. Antom helps global merchants like Booking.com navigate this complexity by leveraging its extensive payment channel partnerships and deep knowledge of local payment landscapes.

Antom has established local acquiring capabilities in over 40 countries and regions, enabling businesses to integrate hundreds of payment methods and supports transactions in over 100 currencies. It offers businesses seamless access to a diverse range of global payment options, including credit cards, e-wallets, and local payment solutions. By leveraging AI technology, Antom helps merchants enhance transaction security, optimise foreign exchange risk management, reduce costs, and improve operational efficiency through real-time payments and blockchain solutions. Additionally, Antom provides digitisation and digital marketing solutions to support merchants’ business growth.

Booking.com is committed to making it easier to experience the world, with a smooth and seamless payment process being a key factor in enabling travellers to book with ease and confidence. Through its partnership with Antom, the digital travel platform will make over 40 payment options available over time, including online banking, bank transfers, digital wallets and local card payments. Key mobile wallets such as AlipayHK (Hong Kong SAR, China), Boost (Malaysia), GCash (the Philippines), GrabPay (Singapore), Kakao Pay (South Korea), Naver Pay (South Korea), Touch 'n Go eWallet (Malaysia) and TrueMoney (Thailand) will be the first to be introduced as new payment methods. This added flexibility empowers a wider range of customers to use their preferred payment methods, streamlining the checkout process and ensuring quicker, more seamless transactions - ultimately unlocking travel opportunities for more consumers across Asia Pacific.

By integrating Antom’s multi-currency offerings and cross-border settlement capabilities, Booking.com is empowering its global accommodation providers to expand user reach, and optimise payment acceptance and reconciliation across diverse markets. This collaboration will especially benefit smaller properties and holiday rentals that may lack access to traditional payment infrastructures, enabling them to compete more effectively in the global marketplace.

Daniel Marovitz, Senior Vice President of Fintech, at Booking.com commented, "Partnering with Antom allows us to streamline and enhance the payment experience for our travellers across Asia Pacific, integrating a wider range of local payment options that align with regional preferences. This collaboration reflects our commitment to delivering a seamless travel experience from booking to checkout. We look forward to working with Antom to support local businesses and continue advancing a more connected, innovative payment ecosystem for travel."

“We’re excited to partner with Booking.com to expand payment options, broaden customer reach across diverse markets, and support the platform in better serving the unique needs of each region,” said Gary Liu, General Manager of Antom, Ant International. “This partnership reflects our commitment to making payments more efficient and enabling merchants to unlock new growth opportunities in today’s dynamic landscape.”

About Booking.com
Part of Booking Holdings Inc. (NASDAQ: BKNG), Booking.com’s mission is to make it easier for everyone to experience the world. By investing in the technology that helps take the friction out of travel, Booking.com’s marketplace seamlessly connects millions of travellers with memorable experiences every day. For more information, follow @bookingcom on social media or visit globalnews.booking.com.

About Antom
Ant International’s Antom is the leading payment and digitisation services provider for merchants around the world. It offers one-stop, vertical-specific digital payment solutions to meet the payment needs of merchants of all sizes. Antom has established local acquiring capabilities in over 40 markets, with the flexibility to accept payments in more than 100 currencies. It also provides digital marketing solutions and merchant digitisation services to help merchant in digital operations and to better engage with their customers. To learn more, please visit https://www.antom.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114445080/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye